Servier options rights to three of MacroGenics' DART compounds; deal ends
Building on a relationship that began with a separate deal almost a year ago, Servier SA has once again optioned rights to early-stage projects from MacroGenics Inc. (therapies for autoimmune and infectious diseases and cancer). This time, the French pharmaco has its sights on three of MacroGenics’ preclinical anticancer DART (Dual-Affinity Re-Targeting) compounds.
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com